LEUKINE® (sargramostim) is the first and only FDA-approved GM-CSF1
GM-CSF=granulocyte-macrophage colony-stimulating factor.
The unique multipotent biology of LEUKINE stimulates multiple immune cell types1
LEUKINE efficacy has been demonstrated in a range of therapeutic settings for patients with hematologic malignancies1
Helpful links and downloadable resources are available
A donation will be made upon completion of the survey to support patients navigating the transplant journey.
Adverse events occurring in >10% of patients receiving LEUKINE in controlled clinical trials and reported in a higher frequency than placebo are:
LEUKINE is a leukocyte growth factor indicated for the following uses:
Please see full Prescribing Information for LEUKINE.
Adverse events occurring in >10% of patients receiving LEUKINE in controlled clinical trials and reported in a higher frequency than placebo are:
LEUKINE is a leukocyte growth factor indicated for the following uses:
Please see full Prescribing Information for LEUKINE.
Reference: 1. Leukine [package insert]. Boston, MA: Partner Therapeutics, Inc.; 2018.